Asset Details
Do you wish to reserve the book?
TIGIT agonism as a therapeutic strategy to suppress inflammation in hidradenitis suppurativa
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
TIGIT agonism as a therapeutic strategy to suppress inflammation in hidradenitis suppurativa
Do you wish to request the book?
TIGIT agonism as a therapeutic strategy to suppress inflammation in hidradenitis suppurativa
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
TIGIT agonism as a therapeutic strategy to suppress inflammation in hidradenitis suppurativa
2026
Overview
Hidradenitis suppurativa (HS) is a chronic, heterogeneous inflammatory skin disorder with limited therapeutic options. The immune checkpoint receptor TIGIT is emerging as a regulator of chronic inflammation, yet its role in HS remains unknown. Here, we investigated TIGIT and its ligands in HS using tissue profiling, transcriptomics, and an ex vivo functional explant model. A tissue microarray containing 52 HS, 9 ruptured follicular cysts, and 4 normal skin samples demonstrated significantly increased TIGIT expression in HS lesions. In contrast, the TIGIT ligand PVRL3 was significantly decreased in HS, a finding also observed in a publicly available RNA-seq dataset. Because TIGIT suppresses inflammation only when adequately engaged by its ligands, reduced PVRL3 may impair inhibitory checkpoint signaling in HS. To test whether TIGIT engagement could suppress HS inflammation, we developed an ex vivo explant model using freshly obtained HS lesional tissue. The system was validated using triamcinolone, a corticosteroid, which consistently reduced IL-6 production. Treatment with a TIGIT agonist antibody significantly reduced IL-6 by 72 hours. These findings provide the first functional evidence that TIGIT activation attenuates inflammatory pathways in HS, supporting TIGIT agonism as a potential therapeutic strategy.
Publisher
Frontiers Media SA,Frontiers Media S.A
Subject
/ Antigens
/ Cysts
/ Enzymes
/ Female
/ Gender
/ Hidradenitis Suppurativa - drug therapy
/ Hidradenitis Suppurativa - genetics
/ Hidradenitis Suppurativa - immunology
/ Hidradenitis Suppurativa - metabolism
/ Hidradenitis Suppurativa - pathology
/ Humans
/ Ligands
/ Male
/ PVRL3
/ Receptors, Immunologic - agonists
/ Receptors, Immunologic - genetics
/ Receptors, Immunologic - metabolism
/ TIGIT
